Remove 2018 Remove Drug Pricing Remove Packaging
article thumbnail

Warnings for Japanese pharmaceutical market may lead to more lenient price controls

Pharmaceutical Technology

According to the report, five member companies decided to decrease their investment in Japan between 2016 and 2017, four companies changed their investment targets between 2018 and 2020, and one company lowered the priority given to Japan after 2021. The MHLW is currently proposing discussions on the FY2023 drug price revision.

article thumbnail

Warnings for Japanese pharmaceutical market may lead to more lenient price controls

Pharmaceutical Technology

According to the report, five member companies decided to decrease their investment in Japan between 2016 and 2017, four companies changed their investment targets between 2018 and 2020, and one company lowered the priority given to Japan after 2021. The MHLW is currently proposing discussions on the FY2023 drug price revision.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Economic unrest results in an average pharmaceutical price trend of 1,123% in Lebanon

Pharmaceutical Technology

Consequentially, the five-year average price trend in Lebanon for all medicines has increased to 1,123%. GlobalData reviews the key events leading up to these current price trends in Lebanon. As this reduction of subsidies coincided with the weakening of the Lebanese pound, it resulted in further heavy price increases.

article thumbnail

To carve in or carve out? Finding the best pharmacy benefit plan for you

HealthPartners

This integrated approach keeps everything together in one package that is coordinated by your primary medical health plan vendor. Represents 2018 performance, latest published figure. For example, members can compare drug prices at pharmacies or find a network provider. What does it mean to carve in pharmacy?

article thumbnail

340B Outlook For 2024: Change. Change. And More Change.

Proxsys Rx

Two potential 340B developments for 2024 In an article dated January 5, the subscriber-only website 340B Report projected that “In 2024, congressional gridlock and election year dynamics will likely slow momentum on any comprehensive 340B program reform package.”

article thumbnail

340B Outlook For 2024: Change. Change. And More Change.

Proxsys Rx

Two potential 340B developments for 2024 In an article dated January 5, the subscriber-only website 340B Report projected that “In 2024, congressional gridlock and election year dynamics will likely slow momentum on any comprehensive 340B program reform package.”

article thumbnail

Antitrust – the independent pharmacist’s role in the fight for open markets, transparency, and strong small businesses

Ramblings of a pharmacist

At the same time, we see our neighbors complain about rising drug prices, and the rising cost of health insurance: Restaurateurs complain a lot about GrubHub and their seller fees, their menu stealing, and their ghost kitchens. We complain about DIR fees. About financial middlemen who add no value but extract plenty.